Insider Buying: CalciMedica, Inc. (NASDAQ:CALC) CEO Purchases $75,000.00 in Stock

CalciMedica, Inc. (NASDAQ:CALC) CEO A. Rachel Leheny acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average cost of $3.75 per share, with a total value of $75,000.00. Following the purchase, the chief executive officer now owns 130,926 shares in the company, valued at $490,972.50. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

A. Rachel Leheny also recently made the following trade(s):

• On Tuesday, August 27th, A. Rachel Leheny purchased 1,000 shares of CalciMedica stock. The shares were bought at an average price of $4.19 per share, with a total value of $4,190.00.

CalciMedica Stock Down 5.1 %

Shares of CalciMedica stock opened at $3.51 on Monday. The stock has a market cap of $37.73 million, a price-to-earnings ratio of -2.51 and a beta of 1.30. CalciMedica, Inc. has a twelve month low of $2.14 and a twelve month high of $8.38. The company’s fifty day moving average is $4.25 and its 200 day moving average is $4.63.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. As a group, equities analysts anticipate that CalciMedica, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Trading of CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Atria Investments Inc raised its position in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the period. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 as of its most recent filing with the SEC.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CALC. Oppenheimer boosted their price objective on CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 10th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of CalciMedica in a research note on Tuesday, August 13th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.